1. The Pathophysiology Department, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450000, China 2. The China-US (Henan) Hormel Cancer Institute, Zhengzhou 450000, China 3. State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou 450000, China 4. Provincial Cooperative Innovation Center for Cancer Chemoprevention, Zhengzhou University, Zhengzhou 450000, China 5. Cancer Chemoprevention International Collaboration Laboratory, Zhengzhou 450000, China 6. Oncology Department, The Tumor Hospital of Linzhou City, Linzhou 456500, China
Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer death worldwide. It is urgent to develop new drugs to improve the prognosis of ESCC patients. Here, we found benzydamine, a locally acting non-steroidal anti-inflammatory drug, had potent cytotoxic effect on ESCC cells. Benzydamine could suppress ESCC proliferation in vivo and in vitro. In terms of mechanism, CDK2 was identified as a target of benzydamine by molecular docking, pull-down assay and in vitro kinase assay. Specifically, benzydamine inhibited the growth of ESCC cells by inhibiting CDK2 activity and affecting downstream phosphorylation of MCM2, c-Myc and Rb, resulting in cell cycle arrest. Our study illustrates that benzydamine inhibits the growth of ESCC cells by downregulating the CDK2 pathway.
Z Yuan, X Wang, X Geng, Y Li, J Mu, F Tan, Q Xue, S Gao, J He. Liquid biopsy for esophageal cancer: is detection of circulating cell-free DNA as a biomarker feasible?. Cancer Commun (Lond) 2021; 41(1): 3–15 https://doi.org/10.1002/cac2.12118
pmid: 33264481
M di Pietro, MI Canto, RC Fitzgerald. Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: screening, diagnosis, and therapy. Gastroenterology 2018; 154(2): 421–436 https://doi.org/10.1053/j.gastro.2017.07.041
pmid: 28778650
5
ZW Reichenbach, MG Murray, R Saxena, D Farkas, EG Karassik, A Klochkova, K Patel, C Tice, TM Hall, J Gang, HP Parkman, SJ Ward, MP Tétreault, KA Whelan. Clinical and translational advances in esophageal squamous cell carcinoma. Adv Cancer Res 2019; 144: 95–135 https://doi.org/10.1016/bs.acr.2019.05.004
pmid: 31349905
P Desai, NJ Thumma, PR Wagh, S Zhan, D Ann, J Wang, S Prabhu. Cancer chemoprevention using nanotechnology-based approaches. Front Pharmacol 2020; 11: 323 https://doi.org/10.3389/fphar.2020.00323
pmid: 32317961
8
A Ranjan, S Ramachandran, N Gupta, I Kaushik, S Wright, S Srivastava, H Das, S Srivastava, S Prasad, SK Srivastava. Role of phytochemicals in cancer prevention. Int J Mol Sci 2019; 20(20): 4981 https://doi.org/10.3390/ijms20204981
pmid: 31600949
9
CY Chen, CJ Kuo, YW Lee, F Lam, KW Tam. Benzydamine hydrochloride on postoperative sore throat: a meta-analysis of randomized controlled trials. Can J Anaesth 2014; 61(3): 220–228 https://doi.org/10.1007/s12630-013-0080-y
pmid: 24263969
10
EB Faber, N Wang, GI Georg. Review of rationale and progress toward targeting cyclin-dependent kinase 2 (CDK2) for male contraception†. Biol Reprod 2020; 103(2): 357–367 https://doi.org/10.1093/biolre/ioaa107
pmid: 32543655
G Au-Yeung, F Lang, WJ Azar, C Mitchell, KE Jarman, K Lackovic, D Aziz, C Cullinane, RB Pearson, L Mileshkin, D Rischin, AM Karst, R Drapkin, D Etemadmoghadam, DDL Bowtell. Selective targeting of cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin Cancer Res 2017; 23(7): 1862–1874 https://doi.org/10.1158/1078-0432.CCR-16-0620
pmid: 27663592
14
S Tadesse, AT Anshabo, N Portman, E Lim, W Tilley, CE Caldon, S Wang. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov Today 2020; 25(2): 406–413 https://doi.org/10.1016/j.drudis.2019.12.001
pmid: 31839441
D Gfeller, A Grosdidier, M Wirth, A Daina, O Michielin, V Zoete. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res 2014; 42: W32–W38 https://doi.org/10.1093/nar/gku293
pmid: 24792161
17
A Grosdidier, V Zoete, O Michielin. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 2011; 39: W270–W277 https://doi.org/10.1093/nar/gkr366
pmid: 21624888
Y Hu, F Liu, X Jia, P Wang, T Gu, H Liu, T Liu, H Wei, H Chen, J Zhao, R Yang, Y Chen, Z Dong, K Liu. Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3. Oncogene 2021; 40(23): 3942–3958 https://doi.org/10.1038/s41388-021-01817-2
pmid: 33986510
20
Y Jiang, Q Wu, X Yang, J Zhao, Y Jin, K Li, Y Ma, X Chen, F Tian, S Zhao, J Xu, J Lu, X Yin, K Liu, Z Dong. A method for establishing a patient-derived xenograft model to explore new therapeutic strategies for esophageal squamous cell carcinoma. Oncol Rep 2016; 35(2): 785–792 https://doi.org/10.3892/or.2015.4459
pmid: 26718633
21
G Jin, M Yan, K Liu, K Yao, H Chen, C Zhang, Y Yi, K Reddy, DR Gorja, KV Laster, Z Guo, Z Dong. Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer. Oncogene 2020; 39(43): 6733–6746 https://doi.org/10.1038/s41388-020-01467-w
pmid: 32963350
22
MG Sürmen, S Sürmen, A Ali, SG Musharraf, N Emekli. Phosphoproteomic strategies in cancer research: a minireview. Analyst (Lond) 2020; 145(22): 7125–7149 https://doi.org/10.1039/D0AN00915F
pmid: 32996481
23
J Ma, T Chen, S Wu, C Yang, M Bai, K Shu, K Li, G Zhang, Z Jin, F He, H Hermjakob, Y Zhu. iProX: an integrated proteome resource. Nucleic Acids Res 2019; 47(D1): D1211–D1217 https://doi.org/10.1093/nar/gky869
pmid: 30252093
24
M Kanehisa, M Furumichi, M Tanabe, Y Sato, K Morishima. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 2017; 45(D1): D353–D361 https://doi.org/10.1093/nar/gkw1092
pmid: 27899662
25
SK Burley, HM Berman, GJ Kleywegt, JL Markley, H Nakamura, S Velankar. Protein Data Bank (PDB): the single global macromolecular structure archive. Methods Mol Biol 2017; 1607: 627–641 https://doi.org/10.1007/978-1-4939-7000-1_26
pmid: 28573592
26
O Trott, AJ Olson. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31(2): 455–461
pmid: 19499576
27
H Sung, J Ferlay, RL Siegel, M Laversanne, I Soerjomataram, A Jemal, F Bray. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209–249 https://doi.org/10.3322/caac.21660
pmid: 33538338
28
V Cioli, C Corradino, P Scorza Barcellona. Review of pharmacological data on benzydamine. Int J Tissue React 1985; 7(3): 205–213
pmid: 3899969
NP Singh, JK Makkar, V Wourms, PM Singh. Topical benzydamine for preventing postoperative sore throat. Anaesthesia 2018; 73(10): 1297 https://doi.org/10.1111/anae.14437
pmid: 30216428
31
H V Worthington. , Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A, McCabe MG, Meyer S, Khalid T, Riley P. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane database Syst Rev 2011; 2011(4): CD000978
T Tsuji, SB Ficarro, W Jiang. Essential role of phosphorylation of MCM2 by Cdc7/Dbf4 in the initiation of DNA replication in mammalian cells. Mol Biol Cell 2006; 17(10): 4459–4472 https://doi.org/10.1091/mbc.e06-03-0241
pmid: 16899510
PL Garcia, AL Miller, KJ Yoon. Patient-derived xenograft models of pancreatic cancer: overview and comparison with other types of models. Cancers (Basel) 2020; 12(5): 1327 https://doi.org/10.3390/cancers12051327
pmid: 32456018
39
S Klöß, S Dehmel, A Braun, MJ Parnham, U Köhl, S Schiffmann. From cancer to immune-mediated diseases and tolerance induction: lessons learned from immune oncology and classical anti-cancer treatment. Front Immunol 2020; 11: 1423 https://doi.org/10.3389/fimmu.2020.01423
pmid: 32733473
40
M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, RB Clarke, Jong S de, J Jonkers, GM Mælandsmo, S Roman-Roman, J Seoane, L Trusolino, A Villanueva. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014; 4(9): 998–1013 https://doi.org/10.1158/2159-8290.CD-14-0001
pmid: 25185190
41
TO Nielsen, SCY Leung, DL Rimm, A Dodson, B Acs, S Badve, C Denkert, MJ Ellis, S Fineberg, M Flowers, HH Kreipe, AV Laenkholm, H Pan, FM Penault-Llorca, MY Polley, R Salgado, IE Smith, T Sugie, JMS Bartlett, LM McShane, M Dowsett, DF Hayes. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 2021; 113(7): 808–819 https://doi.org/10.1093/jnci/djaa201
pmid: 33369635